BioVex to Present at the UBS Global Life Sciences Conference
WOBURN, Mass., Sept. 18 /PRNewswire/ — BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced that Philip Astley-Sparke, President and CEO, is scheduled to present at the UBS Global Life Sciences Conference on Thursday, September 25th at 8:00 A.M. The conference is being held at the Grand Hyatt New York in New York, NY.
BioVex is a privately held biotechnology Company based in Woburn, MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.
The Company’s lead cancer technology platform, OncoVEXGM-CSF is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEXGM-CSF works by: replicating and spreading within solid tumors, causing the death of cancer cells; while stimulating the immune system to destroy metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. BioVex believes OncoVEXGM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data generated to date, coupled with a benign side effect profile.
BioVex is currently completing a Phase II clinical trial of OncoVEXGM-CSF for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Earlier this year, the Company announced that the FDA approved the design of a single, pivotal Phase III clinical trial evaluating OncoVEXGM-CSF in previously treated patients with metastatic melanoma under the Special Protocol Assessment (SPA) procedure and plans to make a second SPA submission for head & neck cancer later in the year. BioVex intends to begin its Phase III trial for OncoVEXGM-CSF in melanoma in the first quarter of 2009.
BioVex recently announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted the Company’s Clinical Trial Application to conduct a Phase I clinical study testing the safety and immunogenicity of its lead infectious disease candidate for genital herpes, ImmunoVEXHSV2, a novel, live-attenuated vaccine. In pre-clinical studies, ImmunoVEXHSV2 completely prevented all symptoms of genital herpes and triggered a powerful immune response, suggesting that ImmunoVEX HSV2 may be more potent than other HSV-2 vaccines for which data has been published.
For further information, please go to http://www.biovex.com/.
CONTACT: Philip Astley-Sparke, President & CEO of BioVex Inc,+1-781-376-4913, email@example.com; or John Capodanno of FD LifeSciences, +1-212-850-5705, firstname.lastname@example.org
Web site: http://www.biovex.com/